TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma

Cancer Science

Volumn 106, Issue 2, 2015, Pages 151-159

  Xiao, Heng ^a   Jiang, Ning ^b   Zhou, Baoyong ^b   Liu, Qiang ^b   Du, Chengyou ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cell; Cell proliferation; Epithelial mesenchymal transition (EMT); Human hepatocellular carcinoma (HCC); TAZ

Indexed keywords

GELATINASE A; GELATINASE B; LENTIVIRUS VECTOR; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CADHERIN; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; SOX2 PROTEIN, HUMAN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ADULT; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL MOTION; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; STEM CELL; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; OCTAMER TRANSCRIPTION FACTOR-3; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS; STEM CELLS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VIMENTIN;

EID: 84927683025     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12587     Document Type: Article

References (35)

1. He J, Gu D, Wu X et al. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124-34.
2. Kanai F, Marignani PA, Sarbassova D et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000; 19: 6778-91.
3. Chan SW, Lim CJ, Guo K et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68: 2592-8.
4. de Cristofaro T, Di Palma T, Ferraro A et al. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer 2011; 47: 926-33.
5. Yuen HF, McCrudden CM, Huang YH et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoS ONE 2013; 8(1): e54211.
6. Bhat KPL, Salazar KL, Balasubramaniyan V et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25: 2594-609.
7. Lei Q-Y, Zhang H, Zhao B et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28: 2426-36.
8. Matteucci E, Maroni P, Luzzati A, Perrucchini G, Bendinelli P, Desiderio MA. Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. Eur J Cancer 2013; 49(1): 231-44.
9. Hong JH, Hwang ES, McManus MT et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005; 309(5737): 1074-8.
10. Cordenonsi M, Zanconato F, Azzolin Luca et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147: 759-72.
11. Hong W, Guan K-L. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012; 23: 785-93.
12. Yang N, Morrison C, Liu P et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 2012; 11: 2922-30.
13. Xiao H, Tong R, Cheng S et al. BAG3 and HIF-1 α coexpression detected by immunohistochemistry correlated with prognosis in hepatocellular carcinoma after liver transplantation. Biomed Res Int 2014; 2014: 9.
14. Xiao H, Cheng S, Tong R et al. BAG3 regulates epithelial-mesenchymal transition and angiogenesis in human hepatocellular carcinoma. Lab Invest 2014; 94: 252-61.
15. Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway. Biochim Biophys Acta, 2013; 1830: 2323-34.
16. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.
17. Mullen AC, Orlando DA, Newman JJ et al. Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell 2011; 147: 565-76.
18. Xu RH, Sampsell-Barron TL, Gu F et al. NANOG is a direct target of TGFβ/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 2008; 3: 196-206.
19. Varelas X, Samavarchi-Tehrani P, Narimatsu M et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev Cell 2010; 19: 831-44.
20. Varelas X, Sakuma R, Samavarchi-Tehrani P et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008; 10: 837-48.
21. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73.
22. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36(13 Spec No): 1621-30.
23. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004; 49: 179-86.
24. Bendinelli P, Maroni P, Matteucci E, Luzzati A, Perrucchini G, Desiderio MA. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur J Cancer 2013; 49: 2608-18.
25. Tang Y, Rowe RG, Botvinick EL et al. MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell 2013; 25: 402-16.
26. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-58.
27. Mimeault M, Batra SK. Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol 2007; 18: 1605-19.
28. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
29. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
30. Varelas X, Miller BW, Sopko R et al. The Hippo pathway regulates Wnt/β-catenin signaling. Dev Cell 2010; 18: 579-91.
31. Brabletz T, Jung A, Reu S et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci 2001; 98: 10356-61.
32. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999; 155: 703-10.
33. Zulehner G, Mikula M, Schneller D et al. Nuclear β-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol 2010; 176: 472-81.
34. Quan MF, Xiao LH, Liu ZH et al. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of beta-catenin. World J Gastroenterol 2013; 19: 7680-95.
35. Jin X-T, Song L, Zhao J-Y, Li Z-Y, Zhao M-R, Liu W-P. Dichlorodiphenyltrichloroethane exposure induces the growth of hepatocellular carcinoma via Wnt/β-catenin pathway. Toxicol Lett 2014; 225(1): 158-66.